Dataset Information

Detection of Brain Tau Pathology in Down Syndrome Using Plasma Biomarkers.

ABSTRACT:

Importance

Novel plasma biomarkers, especially phosphorylated tau (p-tau), can detect brain tau aggregates in Alzheimer disease.

Objective

To determine which plasma biomarker combinations can accurately detect tau pathological brain changes in Down syndrome (DS).

Design, setting, and participants

The cross-sectional, multicenter Alzheimer's Biomarker Consortium-Down Syndrome study included adults with DS and a control group of siblings without DS. All participants with plasma, positron emission tomography (PET), and cognitive measures available by the time of data freeze 1.0 were included. Participants were enrolled between 2016 and 2019, and data were analyzed from August 2021 to April 2022.